Suchergebnisse - "Agarwal, Kosh"

PubPharm (241)

1

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B : REEF-2

enthalten in: Journal of hepatology | 2024

von Agarwal, K. | Buti, M. | van Bömmel, F. | +14

2

Long-term open-label vebicorvir for chronic HBV infection : Safety and off-treatment responses

enthalten in: JHEP reports : innovation in hepatology | 2024

von Yuen, M. | Fung, S. | Ma, X. | +28

3

Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection : A Feasibility Study

enthalten in: Clinical therapeutics | 2024

von Lok, J. | Veloz, M. | Byrne, R. | +4

4

Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

enthalten in: Journal of hepatology | 2024

von Patmore, L. | van Eekhout, K. | Buti, M. | +16

5

Harnessing the power of hepatitis B screening programmes : the I REACH OUT model

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Lok, J. | Martin, C. | Cohen, C. | +3

6

HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

enthalten in: Gastroenterology | 2024

von Sonneveld, M. | Chiu, S. | Park, J. | +26

7

Overview of New Targets for Hepatitis B Virus : Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond

enthalten in: Clinics in liver disease | 2023

von Lok, J. | Guerra Veloz, M. | Agarwal, K.

8

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

enthalten in: JHEP reports : innovation in hepatology | 2023

von Lim, Y. | Chan, H. | Ahn, S. | +21

9

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1) : a multicentre, double-blind, active-controlled, randomised, phase 2b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Yuen, M. | Asselah, T. | Jacobson, I. | +116

CommentIn: Lancet Gastroenterol Hepatol. 2023 Sep;8(9):772-773. - PMID 37442151

10

Hepatitis D virus infection : Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

enthalten in: JHEP reports : innovation in hepatology | 2023

von Lampertico, P. | Degasperi, E. | Sandmann, L. | +24

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[25]